GB-2064

N/A

Report date: 2022/08/22 20:00:20
NME

Base Information

Drug NameGB-2064
Drug Alias NamePAT-1251GB-2064
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysyl oxidase homolog 2 inhibitors
TargetsLysyl oxidase homolog 2
Therapy Area/IndicationsPrimary MyelofibrosisThrombocythemia, EssentialPolycythemia Vera
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyAustralia +[5
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPharmakea Inc
China Registration ClassN/A

Develop Information

Active CompaniesGalecto Biotech AB
Active IndicationsPrimary Myelofibrosis
Inactive IndicationsThrombocythemia, EssentialPolycythemia Vera

Other Information

ATC CodeN/A
Related LinksN/A